Results show a positive screening of previously undetected PAD was independently associated with short-term and long-term increased risks for mortality and major adverse cardiovascular events SANTA CLARA, Calif. , March 1, 2022 /PRNewswire/ -- Semler Scientific, Inc.
SANTA CLARA, Calif. , Dec. 14, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that a study was published in the peer-reviewed AJPM Focus with data
SANTA CLARA, Calif. , March 1, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers (HCPs), today announced the publication of a study in the peer-reviewed Journal of
SANTA CLARA, Calif. , Dec. 12, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced an up to $5.0 million investment in privately-held Monarch Medical
Profitability Continues SAN JOSE, Calif. , May 1, 2018 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three
2019 Q1 HIGHLIGHTS compared to the corresponding period of 2018: - Revenue was $6,761,000, which is an increase of 51% - Net income grew to $0.29 per basic share and $0.23 per diluted share, compared to $0.12 per basic and 0.10 per diluted share - Cash at March 31, 2019 increased to $4,544,000 from
2020 Q1 HIGHLIGHTS compared to the corresponding period of 2019: - Revenues were $9,430,000, which is an increase of 39% - Pre-tax net income of $3,450,000, an increase of $1,596,000, or 86%, compared to $1,854,000 - Net income grew to $0.41 per basic share and $0.33 per diluted share, compared to
2021 Q1 HIGHLIGHTS compared to the corresponding period of 2020: - Revenues were $13.2 million, an increase of 40% - Pre-tax net income of $6.0 million, an increase of $2.5 million, or 74%, compared to $3.5 million - Net income was $4.9 million, or $0.73 per basic share and $0.60 per diluted share,
2022 Q1 HIGHLIGHTS compared to the corresponding period of 2021: Revenues were $14.0 million , an increase of $0.8 million , or 6%, compared to $13.2 million Net income was $3.4 million , or $0.50 per basic share and $0.41 per diluted share, compared to $4.9 million , or $0.73 per basic share and
